FutureCure Health, operator of the NeuroEquilibrium chain of vertigo and balance disorder clinics, has raised ₹104 crore in a funding round led by Carnelian Asset Management LLP. The capital will fuel expansion of its technology-driven diagnostic and treatment network across India and globally, while extending into adjacent chronic conditions like migraine and diabetes.
Glimpse:
The round follows a $4 million Series A in 2022 (led by Kotak Alternate Assets, Unicorn India Ventures, RVCF). FutureCure’s NeuroEquilibrium platform present in 300+ clinics across India and 16 countries has diagnosed and treated over 150,000 patients by pinpointing vertigo causes for targeted therapies. Funds will enhance tech capabilities, deepen hospital partnerships, and broaden access amid frequent misdiagnosis affecting ~60 million Indians.
FutureCure Health, a pioneering health-tech company specializing in super-speciality diagnostics for vertigo and balance disorders, has closed a significant ₹104 crore funding round led by Carnelian Asset Management LLP. This investment marks a pivotal moment for the company as it scales its NeuroEquilibrium brand a wholly owned subsidiary operating a network of advanced clinics focused on precise, root-cause identification and treatment of dizziness-related conditions.
Vertigo and balance disorders impact an estimated six crore Indians, often misdiagnosed or managed only with symptom-suppressing drugs, leading to prolonged suffering. NeuroEquilibrium addresses this through proprietary diagnostic systems that differentiate inner ear, neurological, or vestibular origins enabling condition-specific protocols and better outcomes. The platform collaborates with hospitals, ENT specialists, and neurologists, currently spanning over 300 clinics in India and 16 international markets, having served more than 150,000 patients.
The fresh capital will drive:
Geographic expansion of clinic networks and hospital partnerships in India.
Technological enhancements for scalable, precise diagnostics.
Global market penetration.
Extension into overlapping chronic conditions like migraine and diabetes, where diagnostic complexity and specialist shortages persist.
Co-founders Rajneesh Bhandari (engineer-entrepreneur) and Dr. Anita Bhandari (neurotologist) emphasized technology as a “force multiplier” to bridge specialist gaps: “Precise, scalable diagnostics can democratise super-speciality healthcare.”
This round builds on a $4 million Series A in 2022 from Kotak Alternate Asset Managers, Unicorn India Ventures, and RVCF highlighting sustained investor confidence in FutureCure’s model blending deep-tech with clinical expertise.
The funding arrives amid growing recognition of vertigo’s socioeconomic burden often affecting productive age groups and positions FutureCure to lead in non-invasive, evidence-based solutions for underserved neuro-vestibular care.
“Vertigo/dizziness is often misdiagnosed, leaving patients untreated for years. Our work with 150,000+ patients proves that accurate diagnosis changes outcomes.”
By
HB Team
Related News
